Novo Nordisk (NYSE: NVO) is a leader in the billion-dollar weight loss market, with two drugs that have helped its earnings ...

High prices for anti-obesity drugs known as GLP-1 medications, coupled with high employee demand, are giving employers a lot ...

Patients on Eli Lilly's Mounjaro were more likely to lose weight and experienced larger reductions in body weight compared to ...

The maker of weight-loss jabs Wegovy and Ozempic, Danish pharmaceutical giant Novo Nordisk, has reported a sharp rise in ...

Dr. Lee Kaplan took the stage with an urgent message, telling fellow physicians they have a powerful weapon to fight the ...

Share on Pinterest Diabetes and obesity disproportionately impact Black people, yet they are facing greater challenges gaining access to GLP-1 medications like Ozempic that could help treat these ...

As the popularity of appetite-suppressing drugs like Ozempic and Wegovy continues to skyrocket, one of America's chief snack food overlords is readying himself — and his company's delicious ...

Is the fervor over Ozempic just a passing fad? It doesn't appear to be the case after Novo Nordisk (NYSE: NVO) announced its results for the first nine months of 2023 on Thursday morning.

This section presents medications that are known to potentially lead to 'Throat sore' as a side effect." It's important to note that mild side effects are quite common with medications. Please be ...

Novo Nordisk says it struggling to keep up with demand after becoming Europe’s most valuable company The maker of blockbuster weight-loss drug semaglutide has reported a steep rise in sales and ...

The maker of weight-loss jabs Wegovy and Ozempic, Danish pharmaceutical giant Novo Nordisk, has reported a sharp rise in profits on the back of surging demand for the drugs. Net profits were 39 ...